$RGEN News

Repligen (RGEN) Could Be 12% Undervalued As Record Revenue Lifts Guidance

Record Revenue Outlook Could Be A Game Changer For Repligen (RGEN)

Repligen (RGEN) Takes $41.2 Million Impairment Charge As Quarterly Profit Turns To Loss

Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Is Priced In

Repligen Corporation Q3 2026 Earnings Call Summary

Repligen (RGEN) Q3 2026 Earnings Call Transcript

What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

Repligen: Q3 Earnings Snapshot

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Q3 2026 Earnings Call Transcript

Repligen Corporation 2026 Q3 - Results - Earnings Call Presentation

Repligen Raises FY2026 Adj EPS Guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 Est; Raises FY2026 Sales Guidance from $813.000M-$835.000M to $844.000M-$852.000M vs $829.693M Est

Repligen (RGEN) Q3 earnings report preview: what to look for

Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $180

Repligen: A Buy As Its Growth Engine Gears Up

Repligen to Report Third Quarter 2026 Financial Results

Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Repligen Completes Acquisition of BioLife Solutions